Prostate

Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer (ORIC-944-01)

MOA: ORIC-944 is a highly selective, allosteric, small molecule inhibitor of PRC2 via binding the EED subunit.

• Documented progressive metastatic prostate cancer
• Must have undergone bilateral orchiectomy or be willing to continue
  GnRH analogue or antagonist to maintain castrate levels of testosterone
• Food effect substudies: only 1 prior line of ARPI in any setting and may have received up to 1 prior line of chemo in the mHSPC setting
• Subjects with pure SCC or prostate are excluded
• Dose optimization: Received up to 1 prior line of chemotherapy in the
  mHSPC setting AND:
  • Cohorts A and B: received only one 1 prior line of abiraterone
  • Cohorts C and D: received only one 1 prior line of apalutamide, darolutamide, or enzalutamide

IRONMAN Registry Sub-Study: PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations

Randomized Phase 2b Study of ZEN003694 in Combination with Enzalutamide versus Enzalutamide Monotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer